Clinical Trials

Accrual Status
Limit to SWOG Trials

1027 Results

    View
    Status Trial Number Title Activated Closed Accrual Phase Published
    Open S1900E LUNGMAP S1900E: KRAS Targeted Therapy Sub-Study 4/2/2021 97%
    Open S2005 A Phase II Randomized Study of Ibrutinib and Rituximab with or without Venetoclax in Previously Untreated Waldenstrom's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) 6/24/2021 3%
    Open S1912CD CREDIT 7/26/2021 71%
    Open S2013 I-CHECKIT 8/16/2021 100%
    Closed S1934 NASSIST 9/9/2021 3/1/2023 0%
    Closed S2011 SWOG GAPTrial 10/6/2021 11/15/2023 3%
    Open S2104 A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors 10/14/2021 28%
    Open S2012 II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab in Patients with Poorly Differentiated Extrapulmonary Small Cell NEC 12/2/2021 23%
    Closed S1800D LUNGMAP S1800D: Non-match Sub-Study 2/15/2022 3/10/2023 17%
    Open S2107 Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable… 6/6/2022 73%
    Closed S1900F A Randomized Phase II Study of Carboplatin and Pemetrexed With Or Without Selpercatinib In Patients With Non-Squamous RET Positive Stage IV NSCLC and Progression of Disease On Prior RET Directed Therapy 7/25/2022 6/27/2023 0%
    Open S2108CD Genomic tumor board study 8/22/2022 81%
    Open S2200 S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2 9/19/2022 8%
    Open S2101 BiCaZO - iMATCH pilot 10/14/2022 16%
    Open S2010 ASPEN 1/17/2023 53%
    Open S2114 Ph II consolidation therapy following CD19 CAR-T for R/R DLBCL or Gr III FL 2/23/2023 11%
    Open S2302 PRAGMATICA - LUNG 3/6/2023 65%
    Open EAY191-S3 ComboMATCH S3 3/6/2023 3%
    Open S2205 ICE COMPRESS 3/16/2023 16%
    Open S1900G Comparing Combinations of Targeted Drugs for Advanced NSCLC that has EGFR and MET Gene Changes 4/3/2023 17%
    Scroll Table